OCUL
Price
$9.02
Change
+$0.56 (+6.62%)
Updated
Jun 6 closing price
Capitalization
1.44B
65 days until earnings call
YMAB
Price
$5.27
Change
+$0.17 (+3.33%)
Updated
Jun 6 closing price
Capitalization
238.71M
61 days until earnings call
Interact to see
Advertisement

OCUL vs YMAB

Header iconOCUL vs YMAB Comparison
Open Charts OCUL vs YMABBanner chart's image
Ocular Therapeutix
Price$9.02
Change+$0.56 (+6.62%)
Volume$2.15M
Capitalization1.44B
Y-mAbs Therapeutics
Price$5.27
Change+$0.17 (+3.33%)
Volume$110.17K
Capitalization238.71M
OCUL vs YMAB Comparison Chart
Loading...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
YMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
OCUL vs. YMAB commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OCUL is a Buy and YMAB is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (OCUL: $9.02 vs. YMAB: $5.27)
Brand notoriety: OCUL and YMAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: OCUL: 121% vs. YMAB: 48%
Market capitalization -- OCUL: $1.44B vs. YMAB: $238.71M
OCUL [@Biotechnology] is valued at $1.44B. YMAB’s [@Biotechnology] market capitalization is $238.71M. The market cap for tickers in the [@Biotechnology] industry ranges from $324.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

OCUL’s FA Score shows that 0 FA rating(s) are green whileYMAB’s FA Score has 0 green FA rating(s).

  • OCUL’s FA Score: 0 green, 5 red.
  • YMAB’s FA Score: 0 green, 5 red.
According to our system of comparison, both OCUL and YMAB are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

OCUL’s TA Score shows that 6 TA indicator(s) are bullish while YMAB’s TA Score has 5 bullish TA indicator(s).

  • OCUL’s TA Score: 6 bullish, 4 bearish.
  • YMAB’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, OCUL is a better buy in the short-term than YMAB.

Price Growth

OCUL (@Biotechnology) experienced а +12.61% price change this week, while YMAB (@Biotechnology) price change was +14.57% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.04%. For the same industry, the average monthly price growth was +14.90%, and the average quarterly price growth was +1.90%.

Reported Earning Dates

OCUL is expected to report earnings on Aug 11, 2025.

YMAB is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+9.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OCUL($1.44B) has a higher market cap than YMAB($239M). OCUL YTD gains are higher at: 5.621 vs. YMAB (-32.695). YMAB has higher annual earnings (EBITDA): -30.67M vs. OCUL (-176.35M). OCUL has more cash in the bank: 350M vs. YMAB (67.2M). YMAB has less debt than OCUL: YMAB (820K) vs OCUL (76.2M). YMAB has higher revenues than OCUL: YMAB (87.7M) vs OCUL (59.6M).
OCULYMABOCUL / YMAB
Capitalization1.44B239M601%
EBITDA-176.35M-30.67M575%
Gain YTD5.621-32.695-17%
P/E RatioN/AN/A-
Revenue59.6M87.7M68%
Total Cash350M67.2M521%
Total Debt76.2M820K9,293%
FUNDAMENTALS RATINGS
OCUL vs YMAB: Fundamental Ratings
OCUL
YMAB
OUTLOOK RATING
1..100
2226
VALUATION
overvalued / fair valued / undervalued
1..100
53
Fair valued
36
Fair valued
PROFIT vs RISK RATING
1..100
87100
SMR RATING
1..100
9494
PRICE GROWTH RATING
1..100
4259
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

YMAB's Valuation (36) in the Pharmaceuticals Major industry is in the same range as OCUL (53) in the Pharmaceuticals Other industry. This means that YMAB’s stock grew similarly to OCUL’s over the last 12 months.

OCUL's Profit vs Risk Rating (87) in the Pharmaceuticals Other industry is in the same range as YMAB (100) in the Pharmaceuticals Major industry. This means that OCUL’s stock grew similarly to YMAB’s over the last 12 months.

OCUL's SMR Rating (94) in the Pharmaceuticals Other industry is in the same range as YMAB (94) in the Pharmaceuticals Major industry. This means that OCUL’s stock grew similarly to YMAB’s over the last 12 months.

OCUL's Price Growth Rating (42) in the Pharmaceuticals Other industry is in the same range as YMAB (59) in the Pharmaceuticals Major industry. This means that OCUL’s stock grew similarly to YMAB’s over the last 12 months.

OCUL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as YMAB (100) in the Pharmaceuticals Major industry. This means that OCUL’s stock grew similarly to YMAB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
OCULYMAB
RSI
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
80%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
88%
Momentum
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
82%
MACD
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
81%
Declines
ODDS (%)
Bearish Trend 16 days ago
85%
N/A
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
YMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MACCX16.450.15
+0.92%
MoA Catholic Values Index Fund Class
CSXCX46.28N/A
N/A
Calvert US Large Cap Core Rspnb Idx C
FIICX17.04N/A
N/A
Fidelity Advisor Mid Cap II C
VYMVX17.49N/A
N/A
Voya Mid Cap Research Enhanced Index R
RPMFX15.27N/A
N/A
Reinhart Genesis PMV Advisor

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with EYPT. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
+6.62%
EYPT - OCUL
59%
Loosely correlated
+8.36%
DNLI - OCUL
50%
Loosely correlated
+3.38%
YMAB - OCUL
49%
Loosely correlated
+3.33%
NRIX - OCUL
48%
Loosely correlated
+2.24%
ERAS - OCUL
48%
Loosely correlated
+1.91%
More

YMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, YMAB has been loosely correlated with ARWR. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if YMAB jumps, then ARWR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To YMAB
1D Price
Change %
YMAB100%
+3.33%
ARWR - YMAB
52%
Loosely correlated
+2.13%
CRSP - YMAB
50%
Loosely correlated
+8.53%
FATE - YMAB
48%
Loosely correlated
+19.40%
OCUL - YMAB
48%
Loosely correlated
+6.62%
IMNM - YMAB
47%
Loosely correlated
+0.11%
More